Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.

复杂肢端肥大症患者个性化治疗的长期帕瑞肽 - LAR 治疗 ： 临床经验的集合。

• 发表时间: 2024
• 来源期刊: Drugs Context
• DOI: 10.7573/dic.2024-1-2
• PMID: 38817802
• 文章类型: Journal Article
• 作者列表: Chiloiro S,Appetecchia M,Bianchi A,Costa D,De Acetis C,Gargiulo P,Giampietro A,Isidori AM,Jaffrain-Rea ML,Passeri M,Pigliaru F,Poggi M,De Marinis L

关键词: IGF1; acromegaly; diabetes mellitus; growth hormone; pasireotide-LAR; somatotropinoma

Abstract

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with comorbidities. To provide additional insight on the individualized approach to acromegaly management, six clinical cases of complex acromegaly treated with pasireotide-LAR for more than 5 years were reported. Pasireotide-LAR allowed the normalization of insulin-like growth factor 1 (IGF1) values in all patients and reduced tumour residue volume where present. A good safety profile and long-term tolerability were also reported.

摘要

Pasireotide-LAR建议作为肢端肥大症患者的二线治疗。尽管pasireotide-LAR的作用已在临床研究中得到了很好的表征，实际操作证据很少，特别是在长期和个体化治疗的合并症患者。为了提供有关肢端肥大症管理的个性化方法的更多见解，报告了6例复杂性肢端肥大症的临床病例,治疗时间超过5年.Pasireotide-LAR允许所有患者的胰岛素样生长因子1（IGF1）值正常化，并减少存在的肿瘤残留体积。还报告了良好的安全性和长期耐受性。